Windisch M - Search Results

1

The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease.

Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, Moir RD, Domnitz SB, Frosch MP, Windisch M, Kovacs DM. Hutter-Paier B, et al. Among authors: windisch m. Neuron. 2004 Oct 14;44(2):227-38. doi: 10.1016/j.neuron.2004.08.043. Neuron. 2004. PMID: 15473963 Free article.

2

Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?

Windisch M, Hutter-Paier B, Schreiner E, Wronski R. Windisch M, et al. J Mol Neurosci. 2004;24(1):155-65. doi: 10.1385/JMN:24:1:155. J Mol Neurosci. 2004. PMID: 15314265

3

Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?

Windisch M, Wolf HJ, Hutter-Paier B, Wronski R. Windisch M, et al. Curr Alzheimer Res. 2007 Dec;4(5):556-61. doi: 10.2174/156720507783018343. Curr Alzheimer Res. 2007. PMID: 18220522 Review.

4

The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice.

Huttunen HJ, Havas D, Peach C, Barren C, Duller S, Xia W, Frosch MP, Hutter-Paier B, Windisch M, Kovacs DM. Huttunen HJ, et al. Among authors: windisch m. J Neuropathol Exp Neurol. 2010 Aug;69(8):777-88. doi: 10.1097/NEN.0b013e3181e77ed9. J Neuropathol Exp Neurol. 2010. PMID: 20613640 Free PMC article.

5

A longitudinal study of behavioral deficits in an AβPP transgenic mouse model of Alzheimer's disease.

Havas D, Hutter-Paier B, Ubhi K, Rockenstein E, Crailsheim K, Masliah E, Windisch M. Havas D, et al. Among authors: windisch m. J Alzheimers Dis. 2011;25(2):231-43. doi: 10.3233/JAD-2011-101866. J Alzheimers Dis. 2011. PMID: 21403389 Free PMC article.

6

Influence of Lentiviral β-Synuclein Overexpression in the Hippocampus of a Transgenic Mouse Model of Alzheimer's Disease on Amyloid Precursor Protein Metabolism and Pathology.

Krassnig S, Schweinzer C, Taub N, Havas D, Auer E, Flunkert S, Schreibmayer W, Hutter-Paier B, Windisch M. Krassnig S, et al. Among authors: windisch m. Neurodegener Dis. 2015;15(4):243-57. doi: 10.1159/000430952. Epub 2015 Jun 25. Neurodegener Dis. 2015. PMID: 26111745

7

Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides.

Windisch M, Hutter-Paier B, Rockenstein E, Hashimoto M, Mallory M, Masliah E. Windisch M, et al. J Mol Neurosci. 2002 Aug-Oct;19(1-2):63-9. doi: 10.1007/s12031-002-0012-8. J Mol Neurosci. 2002. PMID: 12212795

8

Current drugs and future hopes in the treatment of Alzheimer's disease.

Windisch M, Hutter-Paier B, Schreiner E. Windisch M, et al. J Neural Transm Suppl. 2002;(62):149-64. doi: 10.1007/978-3-7091-6139-5_15. J Neural Transm Suppl. 2002. PMID: 12456060 Review.

9

Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?

Windisch M, Wolf HJ, Hutter-Paier B, Hofmeister A, Wronski R. Windisch M, et al. Curr Alzheimer Res. 2007 Sep;4(4):446-57. doi: 10.2174/156720507781788783. Curr Alzheimer Res. 2007. PMID: 17908049 Review.

10

Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway.

Huttunen HJ, Peach C, Bhattacharyya R, Barren C, Pettingell W, Hutter-Paier B, Windisch M, Berezovska O, Kovacs DM. Huttunen HJ, et al. Among authors: windisch m. FASEB J. 2009 Nov;23(11):3819-28. doi: 10.1096/fj.09-134999. Epub 2009 Jul 22. FASEB J. 2009. PMID: 19625658 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

223 results

Search Page

Filters